← Leaderboards
Marco L. Davila
Sloan-Kettering Inst Can Research
$1,583,287
Attributed
$2,664,560
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $741.6K · FY2010–25$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,664,560 · 2
By mechanism
R01$2,162,546 · 1
K08$502,014 · 1
Top collaborators
- Brian C Betts3 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Katharine C Hsu$29,362,365
- Dimitar B Nikolov$11,973,314
- Alan M Hanash$10,698,469
- Michael Kharas$18,485,709
- Omar Abdel-Wahab$18,758,829
Others in their field
Top investigators on “Regulatory T-Lymphocyte”
- Barton F Haynes · Duke University$175,178,961
- Steven G. Self · Fred Hutchinson Cancer Research Center$43,947,468
- Joren C Madsen · Massachusetts General Hospital$42,063,899
- Vijay K Kuchroo · Brigham And Women'S Hospital$41,141,362
- Peter Scott Heeger · Case Western Reserve University$35,073,198
- Arlene H Sharpe · Harvard Medical School$34,781,932
Research focus
Regulatory T-LymphocyteB-LymphocytesEffector CellT-LymphocyteClinical TrialsB Lymphoid MalignancyCd19 GeneCyclophosphamideLifeTumorIn VivoInnovationAntigensCell TherapyAntileukemic ActivityAdoptive TransferAntigen ReceptorsAnimal CareAdoptedAcute Graft Versus Host DiseaseBiomarker ValidationBiological MarkersBlood SpecimenAllogenic
Grant awards (6)
Targeting CD83 to reduce leukemia relapse and GVHD after allogeneichematopoietic cell transplantation$711,892
R01 · FY2025 · HL
Targeting CD83 to reduce leukemia relapse and GVHD after allogeneichematopoietic cell transplantation$709,029
R01 · FY2024 · HL
Targeting CD83 to reduce leukemia relapse and GVHD after allogeneic hematopoietic cell transplantation$741,625
R01 · FY2023 · HL
The adoptive transfer of gene-modified T cells as a cell therapy for lymphoma$168,661
K08 · FY2012 · CA · contact PI
The adoptive transfer of gene-modified T cells as a cell therapy for lymphoma$168,661
K08 · FY2011 · CA · contact PI
The adoptive transfer of gene-modified T cells as a cell therapy for lymphoma$164,692
K08 · FY2010 · CA · contact PI